Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population

Journal of Clinical Psychopharmacology
Lori L DavisF Petty

Abstract

To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 +/- 507 mg/d and 82 +/- 30 mg/L, respectively. Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.

References

Jan 1, 1995·Journal of Traumatic Stress·D D BlakeT M Keane
May 20, 1999·Biological Psychiatry·M A HertzbergJ R Davidson
Jun 23, 1999·Journal of Traumatic Stress·R D ClarkV B Tuason
Jan 19, 2002·Journal of Clinical Psychopharmacology·Frederick PettyRobert C Stone
Aug 2, 2002·Clinical Neuropharmacology·Iulian IancuKotler Moshe
Nov 24, 2004·The Journal of Clinical Psychiatry·J Douglas BremnerCharles B Nemeroff
Mar 29, 2006·The Journal of Clinical Psychiatry·Gustavo KinrysMaria Melo
Jan 17, 2007·Journal of Clinical Psychopharmacology·Jonathan R T DavidsonMark H Pollack

❮ Previous
Next ❯

Citations

Mar 23, 2012·Palliative & Supportive Care·James K RustadM Beatriz Currier
May 1, 2010·Expert Review of Clinical Pharmacology·Lindsey I SinclairAndrea L Malizia
May 21, 2009·Expert Opinion on Emerging Drugs·Dewleen G BakerVictoria B Risbrough
Jul 28, 2012·Expert Opinion on Investigational Drugs·Christopher K CainJohn H Kehne
Nov 11, 2009·Journal of Traumatic Stress·Andrew C Leon, Lori L Davis
Aug 3, 2014·International Journal of Psychiatry in Medicine·Heather A Kirkpatrick, Grant M Heller
Aug 9, 2011·Expert Opinion on Pharmacotherapy·Laura C PratchettRachel Yehuda
Aug 7, 2013·Neuroscience Letters·Stephen C HeinrichsGary B Kaplan
Jul 30, 2011·The International Journal of Neuropsychopharmacology·Jonathan C Ipser, Dan J Stein
Aug 26, 2014·Frontiers in Behavioral Neuroscience·Iris MüllerOliver Stork
Jan 15, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·William BergerIvan Figueira
Apr 1, 2009·Brain Research·Lakshmi N Ravindran, Murray B Stein
May 1, 2012·Journal of Pharmacy Practice·Adam Michael Spaulding
Jul 28, 2017·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Valerie Bertaina-AngladeEmile Andriambeloson
Jun 16, 2015·The Journal of Nervous and Mental Disease·Julia McDougal RonconiBradley V Watts
Aug 19, 2014·Human Psychopharmacology·Hee Ryung WangWon-Myong Bahk
Nov 15, 2018·Journal of Psychiatric Practice·Paul J RosenfieldLisa Litt
Dec 21, 2019·The Mental Health Clinician·Megan Ehret
Sep 15, 2020·Health Technology Assessment : HTA·Hollie MeltonPeter Coventry
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Sep 21, 2012·JAAPA : Official Journal of the American Academy of Physician Assistants·Sheryl Alexander, Susan Kuntz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.